About this Research Topic
What have we learned from all the novel gene targets identified by genome-wide association studies (GWAS) about their function, link to certain diseases, and clinical significance?
Cardiovascular disease and comorbidities, such as lipid disorders and metabolic disease have been linked to many different, but also common, genetic loci in numerous GWAS reports. GWAS have strengthened our understanding of the genetic basis of these polygenic common diseases. In the past several years, exciting new progress has been made utilizing state-of-the-art technologies, including systems biology, network medicine, proteomics, transcriptomics, metabolomics, single cell RNA sequencing, CRISPR/Cas9, genomics and integrative physiology.
New underlying causes and mechanisms of action of these novel genes have been elucidated, and pathways have been identified as potential drug targets. Some of the strongly associated GWAS identified loci harbored genes that were previously unknown to have a function in development of cardiovascular disease. Several of these previously unknown genetic loci are under investigation, but more research is needed. SORT1, TRIB1, GALNT2, FTO, Lp(a), and ANGPTLs are some of the top genes with less known function at the moment.
The aim of this Research Topic is to gather contributions from scientists working in the field of cardiovascular disease who have common interests in elucidating the pathological mechanisms linking the GWAS loci and disease to new mechanistic understanding.
We welcome articles uncovering new insights from genetics to systems biology, single cell analysis to pathophysiology, and mouse models to human clinical trials. This Research Topic is intended to highlight these cutting-edge multi-disciplinary approaches, stimulate new ideas, entice more researchers to join the field, and move forward this exciting and highly significant research field. Original Research, Methods, Review and Mini-Review articles are welcomed.
Cardiovascular disease and comorbidities, such as lipid disorders and metabolic disease have been linked to many different, but also common, genetic loci in numerous GWAS reports. GWAS have strengthened our understanding of the genetic basis of these polygenic common diseases. In the past several years, exciting new progress has been made utilizing state-of-the-art technologies, including systems biology, network medicine, proteomics, transcriptomics, metabolomics, single cell RNA sequencing, CRISPR/Cas9, genomics and integrative physiology.
New underlying causes and mechanisms of action of these novel genes have been elucidated, and pathways have been identified as potential drug targets. Some of the strongly associated GWAS identified loci harbored genes that were previously unknown to have a function in development of cardiovascular disease. Several of these previously unknown genetic loci are under investigation, but more research is needed. SORT1, TRIB1, GALNT2, FTO, Lp(a), and ANGPTLs are some of the top genes with less known function at the moment.
The aim of this Research Topic is to gather contributions from scientists working in the field of cardiovascular disease who have common interests in elucidating the pathological mechanisms linking the GWAS loci and disease to new mechanistic understanding.
We welcome articles uncovering new insights from genetics to systems biology, single cell analysis to pathophysiology, and mouse models to human clinical trials. This Research Topic is intended to highlight these cutting-edge multi-disciplinary approaches, stimulate new ideas, entice more researchers to join the field, and move forward this exciting and highly significant research field. Original Research, Methods, Review and Mini-Review articles are welcomed.
Keywords: cardiovascular disease, lipid disorders and metabolic disease, GWAS hit genes, drug targets, clinical implications, network medicine, systems biology
Important Note: All contributions to this Research Topic must be within the scope of the section and journal to which they are submitted, as defined in their mission statements. Frontiers reserves the right to guide an out-of-scope manuscript to a more suitable section or journal at any stage of peer review.
